Brief Patient Health Questionnaire

1. Abstract

The Brief Patient Health Questionnaire (Brief PHQ) is a condensed, self-administered diagnostic and screening instrument derived from the full Patient Health Questionnaire (PHQ) and the Primary Care Evaluation of Mental Disorders (PRIME-MD) diagnostic system. Designed primarily for rapid utilization in busy primary care clinics, ambulatory internal medicine units, and obstetrics/gynecology practices, the Brief PHQ evaluates the most prevalent psychiatric conditions encountered in non-psychiatric medical settings: depressive disorders, panic-spectrum anxiety disorders, psychosocial stressors, interpersonal trauma, and women’s health-related affective disturbances. The core mood component utilizes the validated 9-item depression module (PHQ-9), which directly maps onto the nine diagnostic criteria for Major Depressive Episode articulated in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV / DSM-5). This section employs a 4-point ordinal polytomous response scale assessing symptom frequency over the preceding two weeks (0 = Not at all to 3 = Nearly every day). The anxiety section incorporates a structured branching algorithmic module designed to detect the hallmark physical and cognitive features of panic attacks over a 4-week window. Additionally, the instrument contains a single-item global functional impairment index, a 10-item inventory of common psychosocial stressors rated on a 3-point bother scale, direct screening probes for interpersonal violence and domestic physical/sexual assault, an open-ended index of primary stressors, an inquiry into psychotropic medication usage, and an optional gynecological/reproductive health module tailored to premenstrual dysphoric symptoms, pregnancy status, and postpartum distress. Psychometric evaluations across diverse medical cohorts, including chronic disease populations such as diabetes mellitus, reveal excellent internal consistency for the depressive dimension (Cronbach’s $\alpha = 0.88$ to $0.89$), robust test-retest reliability ($r = 0.84$), and pronounced criterion validity against independent structured psychiatric clinical interviews, showing diagnostic sensitivity and specificity values exceeding 80% to 88% for major depressive and panic syndromes. Consequently, the Brief PHQ serves as a cornerstone of measurement-based psychiatric care across global healthcare systems.

2. Keywords

Brief Patient Health Questionnaire, Brief PHQ, PHQ-9, PRIME-MD, Major Depressive Disorder, Panic Disorder, Primary Care Screening, Psychometrics, Functional Impairment, Psychosocial Stressors

3. Authors

The Brief Patient Health Questionnaire was conceptualized, developed, and clinically validated by a multidisciplinary team of distinguished academic psychiatrists, internists, and psychiatric biostatisticians:

• Robert L. Spitzer, M.D. (1932–2015): Professor Emeritus of Psychiatry, Department of Psychiatry, Columbia University College of Physicians and Surgeons; former Chief of the Department of New Research Approaches, New York State Psychiatric Institute. Dr. Spitzer was the architect of DSM-III and a pioneering figure in operationalized psychiatric diagnostic criteria. Email for historical scholarly inquiries: [email protected].
• Kurt Kroenke, M.D., MACP: Chancellor’s Professor of Medicine, Indiana University School of Medicine; Senior Research Scientist, Regenstrief Institute; Research Physician, Department of Veterans Affairs Health Services Research and Development Service, Indianapolis, IN. Dr. Kroenke is a world-renowned authority on somatic symptom disorders, depression, and patient-reported outcomes in general medicine.
• Janet B. W. Williams, Ph.D., DSW: Professor Emerita of Clinical Psychiatric Social Work, Department of Psychiatry, Columbia University College of Physicians and Surgeons; Research Scientist, New York State Psychiatric Institute. Dr. Williams was instrumental in the field trial methodology of DSM-III-R and DSM-IV.
• Collaborating Clinicians and Methodologists: Including Mark Linzer, M.D., Steven R. Hahn, M.D., David deGruy III, M.D., and Frank V. deGruy, M.D., along with clinical trial support through educational grants administered by Pfizer Inc.

4. Purpose

The primary clinical and epidemiological objective of the Brief PHQ is to overcome the historical barriers of under-recognition, under-diagnosis, and undertreatment of common mental disorders in ambulatory primary care and specialty medical clinics. In standard general medicine environments, up to 50% of major depressive and anxiety disorders fail to be detected during routine consultations due to clinical time constraints, somatic presentation of emotional distress, and physician reluctance to initiate complex, open-ended psychiatric interviews. The Brief PHQ solves this clinical bottleneck by transferring the initial diagnostic screening burden from clinician-administered clinical interviews—such as the original, clinician-dependent PRIME-MD—to a fully self-administered, patient-completed clinical questionnaire that requires between 3 to 5 minutes to complete.

The measurement tool serves both diagnostic and severity monitoring functions. Diagnostically, the questionnaire operationalizes the DSM criterion-based algorithms for Major Depressive Disorder, Other Depressive Disorder, and Panic Disorder without demanding that the primary care clinician memorize intricate multiaxial diagnostic algorithms. In terms of severity tracking, the depressive section functions as a dimensional index (the PHQ-9 continuous score ranging from 0 to 27) that allows physicians to quantitatively monitor treatment response, titration of antidepressant pharmacotherapy, and clinical remission in alignment with measurement-based care guidelines.

Beyond affective and anxiety pathology, the purpose of the Brief PHQ extends to holistic clinical biopsychosocial assessment. By evaluating functional disability, general life stressors (e.g., finances, work, marital discord, caregiving burdens), severe psychological trauma, domestic violence victimization, and reproductive endocrine transitions in women (such as premenstrual dysphoria, postpartum states, and perimenopause), the scale provides a panoramic screen of psychosocial risk factors that significantly interact with medical morbidity, patient adherence, and healthcare utilization.

5. Psychological Construct

The Brief PHQ measures a multifaceted psychiatric and behavioral construct grounded in contemporary clinical nosology. Rather than capturing a single latent trait, the tool evaluates several distinct, clinically interacting domains:

Major Depressive Symptom Burden (Cognitive-Affective and Neurovegetative)

Depression within the Brief PHQ is conceptualized as a continuous and categorical clinical construct reflecting the nine DSM diagnostic criteria. This comprises two primary cardinal symptoms: anhedonia (inability to experience pleasure or interest in daily tasks) and depressed mood (pervasive feelings of sorrow, helplessness, or hopelessness). These are accompanied by seven somatic and cognitive-evaluative markers: insomnia or hypersomnia; chronic fatigue or diminished vitality; altered appetite or dysregulated caloric intake; negative self-evaluations (feelings of guilt, personal failure, or worthlessness); executive cognitive disruptions (concentration difficulties); psychomotor agitation or retardation visible to others; and recurring suicidal ideation, death wishes, or self-harm intentions.

Panic-Spectrum Anxiety and Autonomic Hyperarousal

The anxiety construct operationalized in the scale centers specifically on panic pathology rather than diffuse generalized anxiety. It captures sudden, unexpected paroxysms of intense terror or impending doom occurring without an obvious situational trigger (spontaneous attacks “out of the blue”), anticipatory anxiety regarding prospective episodes, and the acute autonomic arousal cascade (e.g., diaphoresis, tachycardia, tachypnea, dyspnea, paresthesias, vertigo, and gastrointestinal distress).

Global Functional Disability

Functional impairment is conceptualized as the degree of behavioral and role limitation induced by the respondent’s reported emotional and physical problems. Grounded in functional capacity theories, this construct assesses the subjective friction encountered in executing workplace obligations, completing household management tasks, and maintaining adaptive interpersonal relationships.

Psychosocial Stress and Life Burden

This construct measures chronic everyday stressors that operate as precipitating or perpetuating factors in psychiatric vulnerability. It captures perceived strain across social, economic, physical, and interpersonal dimensions, including somatic health anxieties, body dysmorphic concerns, sexual dissatisfaction, marital strain, familial caretaking burdens, occupational and academic stress, socioeconomic hardship, perceived lack of emotional support, recent acute adverse life events, and intrusive traumatic memories indicative of post-traumatic stress.

Interpersonal Victimization and Physical/Sexual Assault

This critical safety dimension captures experiences of physical abuse, battery, intimate partner violence, and non-consensual sexual acts occurring within the past year. This construct serves as a sentinel indicator for complex trauma, behavioral vulnerability, and adverse physical and mental health sequelae.

Reproductive and Endocrine-Linked Dysphoria

Recognizing the pronounced biological and psychological interactions between sex hormones and affective vulnerability in female populations, this module operationalizes reproductive life-cycle transitions (e.g., amenorrhea, postpartum phases, perimenopausal fluctuations) and cyclically recurrent affective disruptions consistent with Premenstrual Dysphoric Disorder (PMDD).

6. Theoretical Framework

The Brief PHQ is anchored in two foundational paradigms: the Neo-Kraepelinian operational diagnostic model of psychiatric classification and the Biopsychosocial Model of medicine pioneered by George L. Engel.

The Neo-Kraepelinian Diagnostic Framework

During the development of the DSM-III and DSM-IV, Dr. Robert Spitzer and colleagues championed the shift away from psychoanalytic etiologic inferences toward explicit, descriptive, criteria-based diagnostic categories. This framework assumes that mental disorders represent distinct clusters of observable symptoms and behavioral signs with predictable clinical courses, treatment responses, and functional impacts. The Brief PHQ directly translates these operational criteria into criterion-referenced self-report items. Each question in the mood and panic sections corresponds to an explicit clinical rule: for example, establishing whether five or more of the nine depressive criteria have been present for at least two weeks, with at least one symptom being depressed mood or anhedonia.

The Biopsychosocial Framework

Engel’s biopsychosocial framework posits that somatic pathology, psychological vulnerability, and social environment continuously interact to determine health outcomes. The Brief PHQ explicitly recognizes that in medical patients, depressive and panic symptoms do not occur in an emotional vacuum; rather, they are inextricably linked to physical disease burden, financial strain, domestic environment, and biological endocrine milestones. By situating categorical psychiatric diagnostics alongside indices of everyday stress, interpersonal safety, and reproductive physiology, the Brief PHQ operationalizes an integrated biopsychosocial assessment tailored specifically for healthcare environments.

7. Validity

The validity of the Brief PHQ and its constituent modules has been evaluated across large-scale primary care and specialty medical investigations, demonstrating strong construct, criterion, convergent, and discriminant validity.

Criterion and Diagnostic Validity

The criterion validity of the Brief PHQ was rigorously established during the initial 3,000-patient PRIME-MD 1000 study and subsequent validation trials across diverse primary care clinics and obstetrics/gynecology services. When validated against independent psychiatric evaluations conducted by mental health professionals utilizing structured clinical interviews (such as the SCID), the diagnostic algorithms embedded within the Brief PHQ demonstrated remarkable diagnostic accuracy:

• Major Depressive Disorder: Sensitivity of 0.88 and specificity of 0.88 when evaluated against clinical interviews using a cutoff score of $ge 10$ on the PHQ-9 component, with an area under the receiver operating characteristic curve (AUC) typically between 0.92 and 0.95.
• Panic Disorder: The panic module exhibited a sensitivity of approximately 0.81 and a specificity of 0.99, demonstrating minimal false-positive rates in primary care settings.

Convergent and Construct Validity

Convergent validity has been established by correlating Brief PHQ scores with established psychometric inventories and clinical markers:

• The PHQ-9 depression module correlates strongly with the Beck Depression Inventory ($r = 0.73$ to $0.80$) and the Hamilton Depression Rating Scale ($r = 0.71$ to $0.84$).
• Continuous depression scores show strong, linear, inverse associations with health-related quality of life, as measured by the Medical Outcomes Study Short-Form Health Survey (SF-36). Increments in PHQ-9 severity correlate with systematic decreases across all eight SF-36 functional subscales ($p < 0.001$).

Discriminant and Predictive Validity

The scale effectively discriminates between psychiatric distress and physical disease burden. While medical patients with chronic illnesses (such as diabetes, coronary artery disease, and end-stage renal disease) present elevated somatic complaints, the Brief PHQ successfully separates affective-cognitive markers of depression (e.g., self-blame, anhedonia, suicidal ideation) from standard medical symptoms. Predictively, elevated scores on the Brief PHQ predict higher subsequent primary care visit frequency, higher prescription drug expenditures, increased work absenteeism, and significantly higher risks of 12-month treatment resistance.

8. Reliability

The reliability of the Brief PHQ has been demonstrated across diverse patient cohorts, medical populations, and demographic groups.

Internal Consistency Reliability

Internal consistency metrics for the continuous depressive component of the Brief PHQ are exceptionally high:

• In the landmark primary care validation study of 3,000 patients, Cronbach’s alpha for the depression module was $\alpha = 0.89$. In an independent validation cohort of 3,000 obstetrics-gynecology patients, internal consistency remained identical at $\alpha = 0.88$.
• In disease-specific clinical populations, such as an English-language Diabetes Self-Management Study involving 344 patients with type 2 diabetes mellitus, the observed 9-item scale demonstrated an observed mean of 6.40 ($SD = 5.73$), an observed range of 0 to 23, and a high internal consistency reliability of Cronbach’s $\alpha = 0.88$.

Test-Retest Reliability

Test-retest stability has been demonstrated through readministration protocols. In primary care cohorts completing the questionnaire at baseline and again within 48 to 72 hours via telephone or in-clinic retest, the correlation between continuous depression scores was $r = 0.84$. Diagnostic concordance for major depressive disorder between independent assessments was high, yielding a Cohen’s kappa coefficient of $kappa = 0.65$ to $0.72$, indicating substantial clinical agreement.

Standard Error of Measurement

The Standard Error of Measurement (SEM) across standard primary care applications has been calculated at approximately 1.7 to 2.1 scale points, confirming that changes of 5 or more points on the 27-point depression scale reflect genuine, clinically meaningful change rather than psychometric measurement error.

9. Factor Analysis

Extensive exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) have confirmed the structural validity of the Brief PHQ modules across general medical, psychiatric, and specialized clinical samples.

Unidimensional vs. Bifactor Structure of Depression

While the PHQ-9 component of the Brief PHQ was designed as a unidimensional metric of major depression, factor analytic studies frequently reveal a robust two-factor or bifactor structure:

• Cognitive-Affective Factor: Comprising item 1 (anhedonia), item 2 (depressed mood), item 6 (feelings of failure/guilt), item 7 (trouble concentrating), and item 9 (suicidal ideation). These items typically exhibit factor loadings exceeding $0.68$ to $0.84$.
• Somatic/Neurovegetative Factor: Comprising item 3 (sleep disturbances), item 4 (fatigue/low energy), item 5 (appetite changes), and item 8 (psychomotor retardation/agitation), with factor loadings ranging between $0.55$ and $0.76$.
• Model Fit Indices: In modern CFA studies, a bifactor model featuring one strong general depression factor alongside two orthogonal group factors (cognitive-affective and somatic) consistently yields superior fit indices: Comparative Fit Index ($ ext{CFI}) > 0.96$, Tucker-Lewis Index ($ ext{TLI}) > 0.95$, Root Mean Square Error of Approximation ($ ext{RMSEA}) < 0.05$, and Standardized Root Mean Square Residual ($ ext{SRMR}) < 0.04$. The general factor accounts for over 80% of the common variance, confirming the psychometric defensibility of using a single summative composite score.

Panic and Stressor Factor Independence

Factor analyses encompassing both the depression module and the psychosocial stressor inventory confirm distinct, cleanly separated latent factors. The 10 psychosocial stress items load on an independent “Chronic Life Strain” dimension ($p < 0.001$), with cross-loadings onto the depression factor remaining below $0.25$, demonstrating distinct construct separation.

10. Instrument / Measurement Tool

• Test Type: Multi-module clinical self-report screening and diagnostic questionnaire.
• Target Population: Adults and adolescents (ages 12+) presenting in primary care, general internal medicine, obstetrics/gynecology, emergency departments, or community health settings.
• Administration Format: Paper-and-pencil self-completion or direct digital capture (computer, tablet, web portal).
• Time required: Approximately 3 to 5 minutes.
• Structural Item Count: Multi-section assessment consisting of:
  • Depression Module (PHQ-9): 9 items (a–i or 1–9) evaluated over a 2-week window.
  • Anxiety / Panic Module: 5 branching items (2a–2e) evaluated over a 4-week window.
  • Global Functional Impairment: 1 single-item index (Question 3).
  • Psychosocial Stressors: 10 items (4a–4j) evaluated over a 4-week window.
  • Interpersonal Violence Screen: 1 binary item (Question 5) evaluated over a 12-month window.
  • Primary Open Stressor: 1 qualitative free-text field (Question 6).
  • Psychotropic Medication Usage: 1 binary item (Question 7).
  • Women’s Reproductive Health Module (Optional): 6 structured items (8a–8f) addressing menstrual regularity, premenstrual dysphoria, pregnancy, postpartum status, and fertility.
• Response Scales:
  • PHQ-9 Depression: 4-point Likert scale:
    • 0 = Not at all
    • 1 = Several days
    • 2 = More than half the days
    • 3 = Nearly every day
  • Panic Disorder Module: Binary response options: NO / YES.
  • Functional Impairment Index: 4-point categorical scale:
    • 0 = Not difficult at all
    • 1 = Somewhat difficult
    • 2 = Very difficult
    • 3 = Extremely difficult
  • Psychosocial Stressors Module: 3-point ordinal scale:
    • 0 = Not bothered
    • 1 = Bothered a little
    • 2 = Bothered a lot
  • Trauma, Medication, and Reproductive Health: Binary options: NO / YES, categorical options for menstrual status.
• Scoring and Diagnostic Rules:
  • Continuous Depression Scoring (PHQ-9): Sum of responses across items 1–9 (range 0–27). Missing item rule: If more than 1 item is missing, the entire scale score is set to missing. If two consecutive numbers are marked by the respondent, the higher (more severe) number is scored; non-consecutive multiple marks are discarded. Standard clinical cutoffs:
    • 0–4: None to minimal depression
    • 5–9: Mild depression
    • 10–14: Moderate depression
    • 15–19: Moderately severe major depression
    • 20–27: Severe major depression
  • Categorical DSM Algorithm for Major Depressive Disorder: Requires 5 or more of the 9 depression items to be endorsed at $ge 2$ (“More than half the days”), with item 9 (suicidal ideation) counting if endorsed at $ge 1$ (“Several days”), and at least one endorsed symptom being item 1 (anhedonia) or item 2 (depressed mood).
  • Panic Disorder Algorithm: Positive screen requires affirmative (‘YES’) responses to all four core questions: 2a (sudden panic attack in last 4 weeks), 2b (prior history of attacks), 2c (attacks occurring ‘out of the blue’), and 2d (worry or concern about future attacks), alongside endorsement of 4 or more somatic/cognitive symptoms in question 2e.
  • Suicide Risk Sentinel: Any endorsement of item 9 ($> 0$) triggers an immediate formal clinical safety protocol.

11. Permissions & Fee and Test Year

The Brief Patient Health Questionnaire and its constituent components were developed in 1999 by Drs. Robert L. Spitzer, Janet B. W. Williams, Kurt Kroenke, and colleagues at Columbia University and collaborating academic medical institutions, funded by an educational grant from Pfizer Inc. The copyright for the instrument is held by Pfizer Inc. (TX221I99G © 1999, Pfizer Inc.).

Licensing and Accessibility: The scale is entirely free to use for clinical, academic, research, and non-commercial educational purposes. The original authors and copyright holders explicitly established that no permission is required to reproduce, translate, display, or distribute the Brief PHQ or the PHQ-9. The trademarks PRIME-MD® and PRIME-MD TODAY® remain registered to Pfizer Inc., but no licensing fees, clinical royalties, or institutional approval fees are levied for utilizing the English or officially translated questionnaire forms.

12. References

• Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x
• Spitzer, R. L., Kroenke, K., & Williams, J. B. (1999). Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. JAMA, 282(18), 1737–1744. https://doi.org/10.1001/jama.282.18.1737
• Spitzer, R. L., Williams, J. B., Kroenke, K., Hornyak, R., & McMurray, J. (2000). Validity and utility of the Patient Health Questionnaire in healthcare settings: A study in 3,000 obstetric-gynecologic patients. American Journal of Obstetrics and Gynecology, 183(3), 759–769. https://doi.org/10.1067/mob.2000.106580
• Kroenke, K., & Spitzer, R. L. (2002). The PHQ-9: A new depression diagnostic and severity measure. Psychiatric Annals, 32(9), 509–515. https://doi.org/10.3928/0048-5713-20020901-06
• Williams, J. B., & Spitzer, R. L. (2002). The Brief Patient Health Questionnaire (Brief PHQ): Clinical applications and research findings. Primary Care Companion to the Journal of Clinical Psychiatry, 4(Suppl 3), 14–20.

13. Items of the Scale (Questionnaire)